Researcher, Molecular Biologist, PhD, #Personalized Medicine #Cancer, #cDNA #PrecisionMedicine
Joined June 2017
- Tweets397
- Following72
- Followers88
- Likes1K
Karin Birkenkamp-Demtröder retweeted
📢 Our newest study on >800 CRC patients is now out 🧬
Read how:
1) Serial ctDNA = powerful recurrence predictor ⏳
2) Rapid ctDNA growth = detrimental to survival 📈
3) Personalized digital PCR = clinically practical for MRD analysis💡
🔗 Read more in @AnnalsofOncology! 📰
New paper out in @Annals_Oncology!
- Postoperative and serial ctDNA detection is prognostic of recurrence
- Several challenges need to be addressed before clinical implementation (stay tuned!)
Outstanding work by @TennaVesterman and the team!
annalsofoncology.org/article…
Karin Birkenkamp-Demtröder retweeted
Our study is finally online @EUplatinum! doi.org/10.1016/j.eururo.202……
▶️Pre-op plasma ctDNA predicts muscle invasive #UTUC on surgical specimen
▶️ctDNA prognostic of post-surgical outcomes
Amazing collaboration with @FaltasLab @AndreaNecchi @JoshMeeks @predicine @MoffittGUOnc
Karin Birkenkamp-Demtröder retweeted
great paper evaluating cTDNA LONG TERM role post +/- NAC and cystectomy of 68 NAC and 102 NAC Naive patients by @LDyrskjot ... lets summarize @CCR_AACR @BladderCancerUS
Karin Birkenkamp-Demtröder retweeted
The November issue is live nature.com/nbt/volumes/41/is…
On the cover, Kirouac et al. encode knowledge about T cell biology through mathematics and use computer simulations to explore the mechanisms underlying clinical observations and biomolecular data go.nature.com/3kEGRqC
Karin Birkenkamp-Demtröder retweeted
New #JITC review: Cell-free DNA approaches for cancer early detection and interception jitc.bmj.com/content/11/9/e0… @ClausLindbjerg @velculescu
Great news!
EV302- enfortumab vedotin and Pembrolizumab met its dual primary endpoints of OS and PFS with ‘clinically meaningful’ improvement versus chemotherapy in patients with previously untreated la/mUC. merck.com/news/merck-announc…
Karin Birkenkamp-Demtröder retweeted
A 3 year postdoc position in bioinformatics and cancer genomics is available in the @LDyrskjot team with focus on translational bladder cancer research and identification of biomarkers for treatment response and outcome using tumor profiling and ctDNA.
au.dk/om/stillinger/job/post…
Karin Birkenkamp-Demtröder retweeted
Milepæl nået🥇
Vi har udgivet genetiske svar på 20.000 patienter
(ikke prøver som kagen siger)!
Denne enorme team-indsats fra både laboratoriet, kliniske akademikere, funktionsledere, sekretærer og alle andre skal selvfølgelig fejres!
Karin Birkenkamp-Demtröder retweeted
This special edition of #SIUJ features Liquid Biopsy in Genitourinary Malignancies. Read the #GiantsInUrology spotlight on Dr. Alvaro Morales and his perspectives on 50 years of BCG in bladder cancer #OpenAccess #Journal 📜Read the July Issue TODAY: bit.ly/3kfexdV
Karin Birkenkamp-Demtröder retweeted
More fantastic work by Dr Li!
Great resource to learn about #ctDNA in GU cancers. Fantastic for an afternoon read this weekend. Thanks @pcvblack @SpiessPhilippe for the opportunity to help put together this issue of @SIU_Journal
bit.ly/3kfexdV
Karin Birkenkamp-Demtröder retweeted
Wanna see something awesome?
Sabrina Ionescu (@sabrina_i20) just scored 37 points in the final round of the 3pt contest.
Nobody, including NBA players have ever done that before.
Karin Birkenkamp-Demtröder retweeted
A preprint of our work on tumor-informed ctDNA based MRD surveillance in bladder cancer using Whole genome mutational analysis. @LDyrskjot @SiaLindskrog @Karin_Dem @moma_dk @C2iGenomics
medrxiv.org/search/MEDRXIV%2…
📖In this book chapter, we describe methods for purification of high-quality #cfDNA and guidelines for designing tumor-informed customized capture panels for sensitive detection of #ctDNA.
@IverNordentoft @Karin_Dem @LDyrskjot
pubmed.ncbi.nlm.nih.gov/3741…
Karin Birkenkamp-Demtröder retweeted
Cancer research breakthrough!
🧬Fragmentation patterns in cfDNA can be used to classify #Cancer types.
🧬This could lead to new, more accurate, and cost-effective ways to diagnose and treat cancer. #MedTwitter @HemOncFellows @Annals_Oncology @OncoAlert @mishabeltran @DrRanaMcKay @felixfengmd @ChristianRolfo
annalsofoncology.org/article…
Karin Birkenkamp-Demtröder retweeted
Highlight: Adaptive Immunity in Genitourinary Cancers
buff.ly/449pcIP
@CanImmun @tbivala1 @pcvblack @MattGalsky @ImmunoBladder @UroDocAsh
#MedTwitter #UroSoMe
Karin Birkenkamp-Demtröder retweeted
På @Folkemoedet i går fortalte @ClausLindbjerg og @LDyrskjot om forskningen i ctDNA guidet kræftbehandling i det nationale samarbejde i @CtdnaDK 🩸🧬
Tak til alle for at møde op og stille gode spørgsmål! 🙌
#ctDNA #CancerResearch #Samarbejdeomkræft
Kan vi bruge kræft dna i blodet til at guide kræftbehandlingen? Spørg @ClausLindbjerg og @LDyrskjot fra @ctdnaDK til #fmdk i @cancer_dk’s telt netop nu #samarbejdeomkræft #dkforsk
Karin Birkenkamp-Demtröder retweeted
👩🎓Julie Rasmussen will defend her Master's thesis on Thu June 22nd 14:30 at MOMA, ground floor auditorium
@Karin_Dem @TBjarnsholt
#bladdercancer #microbiome
Karin Birkenkamp-Demtröder retweeted
Researchers at the Crick and @KingsCollegeLon have made key findings about the way cancer interacts with surrounding immune cells. The findings, which could help discover new immunotherapy targets, were published in @GenomeMedicine
✍️ @hrvshrvs @fcicca
ow.ly/FMz250OJVsk
Karin Birkenkamp-Demtröder retweeted
Today we present our recent data on WGS based ctDNA analyses for monitoring response and detection of relapse in bladder cancer at #ASCO23. Please stop by the poster this morning if you are in Chicago. @IverNordentoft will guide you through the data and results😊 @CtdnaDK
